Acumen Pharmaceuticals, Inc.
ABOS Nasdaq
SEC CIK 1576885
Follow Acumen Pharmaceuticals
Weekly email: filings, results
Net income
−$25.4M
+4.1% vs same quarter last year
EPS, diluted
−$0.35
+20.5% vs same quarter last year
Operating cash flow
−$26.7M
+12.6% vs same quarter last year
Operating income
−$25.8M
+2.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$121.3M |
| FY24 | −$102.3M |
| FY23 | −$52.4M |
| FY22 | −$42.9M |
| FY21 | −$100.6M |
| FY20 | −$7.3M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$115.6M |
| FY24 | −$86.2M |
| FY23 | −$43.1M |
| FY22 | −$35.3M |
| FY21 | −$18M |
| FY20 | - |
| FY19 | - |